Vitamin D Level in Breast Cancer Premenopausal Patients before and after Adjuvant Therapy

Gabr, Hanan Mohamed; Marei, ُElham

doi:10.21608/ejrsa.2017.1210.1013

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison with the control group, we found more patients with VD deficiency (56.1% vs. 37.2%) among the BC patients. Decreased levels of VD in BC patients compared to control subjects were observed previously [ 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ], and our results confirm these findings with the LC–MS/MS methodology. Presented findings could be a result of decreased sun exposure.…”

Section: Discussionsupporting

confidence: 92%

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Kimsa-Furdzik,

Bednarek,

Hibner

et al. 2023

Metabolites

View full text Add to dashboard Cite

Background: The predictive role of vitamin D (VD) in breast cancer (BC) patients’ survival is still being investigated. This paper aims to evaluate the changes in VD metabolites during chemotherapy (CTH) and the predictive role of VD status in Caucasian BC patients treated with CTH. Methods: Vitamin D and its metabolites were assessed with reference LC–MS/MS methodology in 98 consecutive BC patients starting CHT, after 3 and 6 months, and compared to the control group. Results: The frequency of VD deficiency in BC patients was greater than in the control group (56.1% vs. 37.2%). After 6 months of CTH, the number of VD-deficient BC patients slightly increased to 60%. The concentrations of VD active forms [25(OH)D2, 25(OH)D3], and catabolites [24,25(OH)2D3 and 3-epi-25(OH)D3] decreased after 3 and 6 months of CTH compared to the baseline values. Strong positive correlations between concentrations of 3-epi-25(OH)D3 and 25(OH)D in both groups were found. Similar correlations were also observed between 24,25(OH)2D3 and 25(OH)D levels. Kaplan–Meier survival analysis showed significantly longer survival in BC patients without deficiency (>20 ng/mL) at baseline (HR = 2.44 (95% CI 1.07–5.59), p = 0.026). Conclusions: (1) Our data provide further evidence that BC patients before CTH are more VD-deficient than the general population and this deficiency increases further during CTH treatment, as observed using the reference LC-MS methodology. (2) Presented results show that VD catabolism is not affected in BC patients. (3) The poorer survival in VD-deficient BP patients supports the importance of VD supplementation in BC patients with 25(OH)D levels below 20 ng/mL.

show abstract

Section: Discussionsupporting

confidence: 92%

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Kimsa-Furdzik,

Bednarek,

Hibner

et al. 2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…Furthermore, women have substantially more breast cells than men, and therefore have a significantly higher incidence risk. Another risk factor for BC is age, which raises the probability of developing the disease in older people (7). Early detection of BC is the most effective technique for saving lives and lowering healthcare expenditures over time.…”

Section: Introductionmentioning

confidence: 99%

Expression Of Cyclooxygenase-2 And Interlukin-6 Mrnas In Iraqi Patients With Breast Cancer

Hussien

2023

KMJ

View full text Add to dashboard Cite

Background: Breast cancer is one of the most common malignant tumors that endanger women's health internationally, relatively uncommon in men, accounting for only 1% of all cancer cases. Location, way of life, age at marriage, and obesity are a few environmental variables that increase the risk of breast cancer. Aim of study: the study aims to explain how the pro-inflammatory cytokines (IL-6) induce the inflammatory events in patients with breast cancer and to describe whether cyclooxygenase-2 promotes tumor growth in breast cancer or not. Materials and methods: The current case-control cross-sectional study included 45 patients with a history of breast cancer, and it was done in multiple places in Hilla, Babylon Province, between November 2022 and March 2023.Interlukin-6 and Cyclooxygenase-2 by QPCR. Results: The results have shown a significant increase of IL-6 (P < 0.05) in patients compared with control. Also, the results have shown a significant increase (P < 0.05) of COX2 in patients compared with control. Conclusion: There is a significant increase in the means of Interlukin-6 and Cyclooxygenase-2 in the patients with breast cancer.

show abstract

Vitamin D Level in Breast Cancer Premenopausal Patients before and after Adjuvant Therapy

Cited by 2 publications

References 30 publications

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Expression Of Cyclooxygenase-2 And Interlukin-6 Mrnas In Iraqi Patients With Breast Cancer

Contact Info

Product

Resources

About